P.A. Ascierto

735 total citations · 1 hit paper
30 papers, 325 citations indexed

About

P.A. Ascierto is a scholar working on Oncology, Molecular Biology and Organic Chemistry. According to data from OpenAlex, P.A. Ascierto has authored 30 papers receiving a total of 325 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 12 papers in Molecular Biology and 5 papers in Organic Chemistry. Recurrent topics in P.A. Ascierto's work include Cutaneous Melanoma Detection and Management (13 papers), Cancer Immunotherapy and Biomarkers (11 papers) and Melanoma and MAPK Pathways (10 papers). P.A. Ascierto is often cited by papers focused on Cutaneous Melanoma Detection and Management (13 papers), Cancer Immunotherapy and Biomarkers (11 papers) and Melanoma and MAPK Pathways (10 papers). P.A. Ascierto collaborates with scholars based in Italy, France and United States. P.A. Ascierto's co-authors include Pierfranco Conté, Angelo Vanzulli, Alfredo Falcone, Fabio Sandomenico, Michelino De Laurentiis, Paolo Tarsia, Alessia Comes, Daniele Regge, Romano Danesi and Anna Maria Cattelan and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

P.A. Ascierto

27 papers receiving 320 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment

2022 130 citations Pierfranco Conté, P.A. Ascierto et al. ESMO Open profile →

Peers

Countries citing papers authored by P.A. Ascierto

Since Specialization

Citations

This map shows the geographic impact of P.A. Ascierto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P.A. Ascierto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P.A. Ascierto more than expected).

Fields of papers citing papers by P.A. Ascierto

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P.A. Ascierto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P.A. Ascierto. The network helps show where P.A. Ascierto may publish in the future.

Co-authorship network of co-authors of P.A. Ascierto

This figure shows the co-authorship network connecting the top 25 collaborators of P.A. Ascierto. A scholar is included among the top collaborators of P.A. Ascierto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P.A. Ascierto. P.A. Ascierto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	LBA53 IO102-IO103 cancer vaccine plus pembrolizumab for first-line (1L) advanced melanoma: Primary phase III results (IOB-013/KN-D18) 2025 ·Annals of Oncology ·(unknown), Ana Arance, (unknown), P.A. Ascierto, Simran Sandhu, (unknown), (unknown), Omid Hamid, Laurent Mortier, (unknown), (unknown), (unknown), Stephan Grabbe, (unknown), Anita Vedel Christiansen, Biao Wang, Qasim Ahmad, François Ringeisen, (unknown), Inge Marie Svane	0
2	1516MO EVX-01, a personalized cancer vaccine, induces potent T cell responses and durable disease control in advanced melanoma: 2-year follow-up 2025 ·Annals of Oncology ·Muhammad A. Khattak, P.A. Ascierto, Carolina Cimminiello, Michael Chisamore, (unknown), (unknown), Daniela Kleine‐Kohlbrecher, M. Lausen, Michail Pavlidis, Birgitte Rønø, (unknown), Thomas Trolle, (unknown), B.G. Wolthers, (unknown)	0
3	LBA7 The Rome trial from histology to target: The road to personalize targeted therapy and immunotherapy 2024 ·Annals of Oncology ·Andrea Botticelli, (unknown), Pierfranco Conté, (unknown), P.A. Ascierto, (unknown), (unknown), Federica Mazzuca, (unknown), (unknown), (unknown), Marianna Nuti, Giulia d’Amati, (unknown), (unknown), Mauro Biffoni, (unknown), Francesco Cognetti, G. Curigliano, Paolo Marchetti	9
4	1083MO Brain metastases and survival evaluation in the SECOMBIT trial 2023 ·Annals of Oncology ·P.A. Ascierto, Mario Mandalà, Pier Francesco Ferrucci, (unknown), Piotr Rutkowski, Virginia Ferraresi, Ana Arance, Michele Guida, Evaristo Maiello, Helen Gogas, Erika Richtig, Maria Teresa Fierro, Célèste Lebbé, Hildur Helgadóttir, Ignacio Melero, Giuseppe Palmieri, Diana Giannarelli, (unknown), (unknown), (unknown)	5
5	LBA41 Phase II study SECOMBIT (sequential combo immuno and target therapy study): 4-years OS data and preliminary biomarkers evaluation 2022 ·Annals of Oncology ·P.A. Ascierto, Mario Mandalà, Pier Francesco Ferrucci, (unknown), Piotr Rutkowski, Virginia Ferraresi, Ana Arance, Michele Guida, Evaristo Maiello, Helen Gogas, Erika Richtig, (unknown), Célèste Lebbé, Hildur Helgadóttir, Ignacio Melero, Giuseppe Palmieri, Diana Giannarelli, (unknown), R. Dummer, (unknown)	2
6	819P Efficacy of dabrafenib (D) trametinib (T) plus spartalizumab (S) by baseline site of metastases in patients (pts) with previously untreated BRAF V600-mutant unresectable or metastatic melanoma: Post hoc analysis of phase III COMBI-i trial 2022 ·Annals of Oncology ·Paul Nathan, Jean‐Jacques Grob, Reinhard Dummer, P.A. Ascierto, (unknown), Caroline Robert, Dirk Schadendorf, Keith T. Flaherty, (unknown), (unknown), Mario Mandalà, (unknown), Hiya Banerjee, (unknown), Mike Lau, Georgina V. Long	3
7	884TiP A phase Ib/II multicenter, randomized, umbrella study evaluating novel treatment combinations in melanoma (MORPHEUS-MELANOMA) 2022 ·Annals of Oncology ·Georgina V. Long, (unknown), Ahmad A. Tarhini, P.A. Ascierto, (unknown), (unknown), (unknown), Volker Teichgräber, Christian U. Blank	3
8	113P Pembrolizumab in microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) advanced solid tumors: An update of the phase II KEYNOTE-158 trial 2022 ·Annals of Oncology ·Michele Maio, P.A. Ascierto, (unknown), Nicolas Penel, Philippe A. Cassier, Giovanni M. Bariani, Ana De Jesus‐Acosta, Takeshi Doi, (unknown), Wilson H. Miller, (unknown), Maya Gottfried, Lixia Yao, (unknown), Alexander Gozman, (unknown)	3
9	786O Tumor biomarker analysis from COLUMBUS part 1: Encorafenib + binimetinib for BRAF V600E/K-mutant advanced or metastatic melanoma 2022 ·Annals of Oncology ·R. Dummer, Nazima Pathan, Shibing Deng, (unknown), Ana Arance, (unknown), (unknown), Helen Gogas, Ralf Gutzmer, Ivana Krajsová, (unknown), Carmen Loquai, Mario Mandalà, Dirk Schadendorf, (unknown), Alessandra di Pietro, Tao Xie, P.A. Ascierto, (unknown)	2
10	804P Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: 5-year results of the EORTC 1325-MG/Keynote-054 double-blinded phase III trial 2022 ·Annals of Oncology ·Alexander M.M. Eggermont, Michal Kiciński, (unknown), Mario Mandalà, Georgina V. Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, (unknown), Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, (unknown), P.A. Ascierto, Paul Lorigan, Dmitri Grebennik, Nageatte Ibrahim, Sandrine Marréaud, Stefan Suciu, Caroline Robert	1
11	Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment breakdown → 2022 ·ESMO Open ·Pierfranco Conté, P.A. Ascierto, Giorgio Patelli, Romano Danesi, Angelo Vanzulli, Fabio Sandomenico, Paolo Tarsia, Anna Maria Cattelan, Alessia Comes, Michelino De Laurentiis, Alfredo Falcone, Daniele Regge, Luca Richeldi, Salvatore Siena	130
12	LBA40 SECOMBIT: The best sequential approach with combo immunotherapy [ipilimumab (I) /nivolumab (N)] and combo target therapy [encorafenib (E)/binimetinib (B)] in patients with BRAF mutated metastatic melanoma: A phase II randomized study 2021 ·Annals of Oncology ·P.A. Ascierto, Mario Mandalà, Pier Francesco Ferrucci, Piotr Rutkowski, Massimo Guidoboni, Ana Arance, Virginia Ferraresi, Evaristo Maiello, Michele Guida, Michele Del Vecchio, Maria Teresa Fierro, Paola Queirolo, Célèste Lebbé, Hildur Helgadóttir, Ignacio Melero, Giuseppe Palmieri, Diana Giannarelli, Antonio Maria Grimaldi, Reinhard Dummer, (unknown)	18
13	1036O Relatlimab (RELA) + nivolumab (NIVO) vs. NIVO in previously untreated metastatic or unresectable melanoma: Additional efficacy in RELATIVITY-047 2021 ·Annals of Oncology ·F. Stephen Hodi, Hussein A. Tawbi, Evan J. Lipson, Dirk Schadendorf, P.A. Ascierto, Luis Matamala, Eric Gutierrez, Piotr Rutkowski, Helen Gogas, Christopher D. Lao, J. Menezes, Stéphane Dalle, Ana Arance, Jean‐Jacques Grob, Laurence Toms, (unknown), (unknown), Georgina V. Long	4
14	PCN84 COST OF ILLNESS OF CUTANEOUS SQUAMOUS CELL CARCINOMA IN ITALY 2019 ·Value in Health ·Andrea Marcellusi, (unknown), Ketty Peris, P.A. Ascierto, F.S. Mennini	2
15	Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Updated results from a phase 3 trial (CheckMate 238) 2018 ·British Journal of Cancer ·(unknown), Mario Mandalà, M. Del Vecchio, Helen Gogas, Ana Arance, C. Lance Cowey, Stéphane Dalle, (unknown), Vanna Chiarion‐Sileni, Iván Márquez‐Rodas, Jean‐Jacques Grob, Marcus O. Butler, Mark R. Middleton, Michele Maio, Victoria Atkinson, R. Dummer, Veerle de Pril, Anila Qureshi, James Larkin, P.A. Ascierto	1
16	Impact of key prognostic factors on long-term overall survival in BRAFV600-mutated metastatic melanoma patients treated with vemurafenib in the BRIM-3 study 2016 ·Melanoma Research ·Axel Hauschild, Paul B. Chapman, Caroline Robert, James Larkin, J.B.A.G. Haanen, A. Ribas, David Hogg, Omid Hamid, P.A. Ascierto, Alberto Testori, Paul Lorigan, R. Dummer, J. A. Sosman, Keith T. Flaherty, Matthew Wongchenko, (unknown), I‐Fen Chang, (unknown), Ivor Caro, Grant A. McArthur	2
17	Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT) 2016 ·Annals of Oncology ·Philippe Saïag, Ralf Gutzmer, P.A. Ascierto, Michele Maio, Jean‐Jacques Grob, P. Murawa, Brigitte Dréno, M. I. Ross, Jeffrey S. Weber, (unknown), Piotr Rutkowski, Alessandro Testori, E. Levchenko, Alexander Enk, L. Misery, Carline Vanden Abeele, Ivo Vojtek, Olivier Peeters, Vincent Brichard, P. Therasse	20
18	9322 POSTER Immunological and Biological Changes and Their Correlation With Clinical Response and Survival During Ipilimumab in Metastatic Melanoma Compassionate Use Program 2011 ·European Journal of Cancer ·Ester Simeone, Giusy Gentilcore, Alessandro Esposito, Marcello Curvietto, Pedro Antonio de la Rosa, Ermelinda De Maio, Maria Pia Pistillo, Paola Queirolo, N Mozzillo, P.A. Ascierto	3
19	An Assessment of Factors Related to Tumor Thickness and Delay in Diagnosis of Melanoma in Southern Italy 2002 ·Preventive Medicine ·(unknown), Anna Crispo, Maria Grimaldi, (unknown), P.A. Ascierto, Rosanna Parasole, Maria Teresa Melucci, (unknown), Gabriella Fabbrocini	28
20	Low doses interferon-α in the treatment of high-risk cutaneous melanoma 2000 ·Annals of Oncology ·P.A. Ascierto, Giuseppe Palmieri, Maria Strazzullo, Antonio Daponte, Gerardo Botti, (unknown), Maria Letizia Motti, Nicola Mozzillo, (unknown)	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact